JCR Pharmaceuticals announced yesterday that it has launched its biosimilar agalsidase beta product, referencing Fabrazyme, in Japan for the treatment of Fabry disease. JCR developed the drug in partnership with Amicus Therapeutics and GlaxoSmithKline.
JCR Pharmaceuticals announced yesterday that it has launched its biosimilar agalsidase beta product, referencing Fabrazyme, in Japan for the treatment of the lysosomal storage disorder (LSD) Fabry disease (FD). JCR developed the drug in partnership with Amicus Therapeutics and GlaxoSmithKline.
The product, Agalsidase Beta BS IV Infusion, which will be available in 5-mg and 35-mg vials, was approved by Japan’s Ministry of Health, Labor, and Welfare in September 2018. In its announcement of the product’s availability, JCR noted that not only is the product the first biosimilar agalsidase beta, it is also the first product for the treatment of an LSD that will be produced domestically in Japan.
Japanese regulators approved the product on the basis of a data package that included findings from a nonclinical evaluation of the product in comparison with its reference that determined that the amino acid sequence of the products was identical. A higher-order assessment of the structures revealed both molecules to have similar structural properties and comparable enzyme activity. The biosimilar had a similar glycosylation profile to the reference, but the biosimilar demonstrated slightly better cellular uptake of enzymes than the reference did (this fact did not affect pharmacokinetics of efficacy, however).
Like its reference, the biosimilar product is a recombinant human alpha-galactosidase A enzyme replacement therapy for FD, which is a rare inherited disorder that affects 1 in 40,000 to 60,000 men. (While FD can also affect women, its prevalence in female patients is not known.) FD stems from a mutation in the alpha-galactosidase A gene that causes a buildup of globotriaosylceramide in cells. This buildup can adversely affect the functioning of the heart, kidneys, and other organs and lead to cardiac disease, stroke, renal failure, and early death.
Given how critical treatment with agalsidase beta is to control FD, the availability of a biosimilar option will be welcome to patients, who in the past have faced shortages of the reference Fabrazyme. In 2009, a manufacturing process introduced viral contamination into the Sanofi Genzyme reference drug, sparking a global shortage of this crucial therapy.
During the shortage, patients were instructed by the European Medicines Agency to reduce their dosages, but after an increased rate of serious adverse events was observed among FD patients who followed directions to reduce their doses, patients were subsequently asked to switch to other treatment options. In the United States, patients with FD unsuccessfully petitioned the US government to force Sanofi Genzyme to license its patent for Fabrazyme to biosimilar developers in order to create further supply of the treatment.
To date, JCR has not announced whether it will seek European or US regulatory authorization for the biosimilar.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.